Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4.

[1]  E. Carosella,et al.  A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. , 2015, European urology.

[2]  P. Horn,et al.  The Paradox of High Availability and Low Recognition of Soluble HLA-G by LILRB1 Receptor in Rheumatoid Arthritis Patients , 2015, PloS one.

[3]  N. Rouas-Freiss,et al.  HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.

[4]  N. Zhang,et al.  Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10 , 2014, Diagnostic Pathology.

[5]  N. Rouas-Freiss,et al.  The Dual Role of HLA-G in Cancer , 2014, Journal of immunology research.

[6]  J. Lozano,et al.  sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. , 2006, Transplant immunology.

[7]  Kouhei Tsumoto,et al.  Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d) , 2006, Proceedings of the National Academy of Sciences.

[8]  Kouhei Tsumoto,et al.  Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer* , 2006, Journal of Biological Chemistry.

[9]  E. Carosella,et al.  HLA‐G up‐regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  H. Nückel,et al.  HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. , 2005, Blood.

[11]  E. Carosella,et al.  Expression of HLA-G in cancer bladder. , 2005, The Egyptian journal of immunology.

[12]  R. Dummer,et al.  Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. , 2004, Blood.

[13]  H. Grosse-wilde,et al.  Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay , 1989, Blut.

[14]  Kouhei Tsumoto,et al.  Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Dausset,et al.  Specific activation of the non‐classical class I histocompatibility HLA‐G antigen and expression of the ILT2 inhibitory receptor in human breast cancer , 2002, The Journal of pathology.

[16]  J. Dausset,et al.  Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule , 2002, AIDS.

[17]  L. Dubertret,et al.  HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? , 2001, The American journal of pathology.

[18]  J. Dausset,et al.  Characterization of HLA-G1, -G2, -G3, and -G4 isoforms transfected in a human melanoma cell line. , 2001, Transplantation proceedings.

[19]  G. Ogg,et al.  Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. , 1998, Journal of immunology.

[20]  M. Colonna,et al.  A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells , 1997, The Journal of experimental medicine.

[21]  M. Colonna,et al.  Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: Structural evidence for new stimulatory and inhibitory pathways , 1997, European journal of immunology.